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ventricular progenitors and their assembly into a 3-dimen-
sional in vivo functional ventricular heart patch has remained
an elusive goal. Herein, we report the generation of an enriched
pool of hPSC-derived ventricular progenitors (HVPs), which
can expand, differentiate, self-assemble, and mature into a
functional ventricular patch in vivo without the aid of any gel
or matrix. We documented a specific temporal window, in
which the HVPs will engraft in vivo. On day 6 of differentia-
tion, HVPs were enriched by depleting cells positive for plurip-
otency marker TRA-1-60 with magnetic-activated cell sorting
(MACS), and 3 million sorted cells were sub-capsularly trans-
planted onto kidneys of NSG mice where, after 2 months,
they formed a 7 mm 3 mm 4 mmmyocardial patch resem-
bling the ventricular wall. The graft acquired several features of
maturation: expression of ventricular marker (MLC2v), des-
mosomes, appearance of T-tubule-like structures, and electro-
physiological action potential signature consistent with matu-
ration, all this in a non-cardiac environment. We further
demonstrated that HVPs transplanted into un-injured hearts
of NSG mice remain viable for up to 8 months. Moreover,
transplantation of 2 million HVPs largely preserved myocar-
dial contractile function following myocardial infarction.
Taken together, our study reaffirms the promising idea of using
progenitor cells for regenerative therapy.Received 31 January 2018; accepted 11 February 2018;
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Heart failure is a globally leading cause of mortality,1 primarily driven
by the loss of ventricular muscle mass2 and the limited regenerative
ability of the adult heart.3–5 Ventricular muscle tissue engineering
with human pluripotent stem cells (hPSCs), embryonic stem cells
(ESCs), or induced pluripotent stem cells (iPSCs) to create a func-
tional in vivo 3D human ventricular muscle patch holds great1644 Molecular Therapy Vol. 26 No 7 July 2018 ª 2018 The Author(s).
This is an open access article under the CC BY-NC-ND license (htpromise. However, such efforts have been hampered by the require-
ment for large-scale generation of purified ventricular cells as well
as their controlled growth and maturation, vascularization, assembly,
and formation of extracellular matrix (ECM).6 To date, diverse car-
diovascular cells, ECMs, de-cellularized scaffolds, and DNA/RNAs
have been studied for therapeutic use, and 3D in vitro perfused heart
models have been generated, but the generation of a vascularized,
functional ventricular wall in the in vivo context has remained elusive.
Previous studies with hPSCs have been based on the generation of
heart tissue constructs from already differentiated cardiomyocytes
rather than committed ventricular lineage progenitors. Importantly,
lineage progenitors may have intrinsic properties for triggering
vascular and matrix cues critical for self-assembly and formation of
an in vivo stable niche, which are lost during later stages of differen-
tiation. In this regard, other attempts to form in vivo grafts have
required the addition of other synthetic matrices, gels, suturing into
the ventricular wall, scaffolds, or additional interstitial-like cells to
allow the cells to remain within the contractile ventricular wall. On
the other hand, most well-characterized heart progenitors are
multi-potent,7,8 and most protocols result in a mixture of atrial, ven-
tricular, pacemaker, vascular smooth muscle, and endothelial
lineages.9,10 Early-stage progenitors are also usually contaminated
with pluripotent stem cells,11 raising the danger of teratoma forma-










Figure 1. hPSC-Derived HVPs by Modulation of Wnt Signaling via Small Molecules
(A) Schematic protocol for defined differentiation of hPSCs to ventricular progenitors. (B) Brachyury expression was detected on day 1. (C) MESP1 expression was detected
on day 3 with flow cytometry. (D and E) 14 days after initiation of hPSC differentiation using the protocol shown above, cells were analyzed for MLC2v (D) and cTnT (E)
(legend continued on next page)
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Molecular Therapybeen documented in transplantation studies.13 Finally, it remains un-
clear as to whether the transplantation of progenitors in vivo would
result in their subsequent loss of progenitor markers and subsequent
differentiation, vascularization, matrix formation, grafting without
additional cell/matrix/scaffolds, and early steps of maturation.
Although human iPS or ES-derived functional motor neurons,14
pancreatic b cells,15 and organoids16 have been generated in vitro,
the in vivo generation of an ESC-derived multicellular organ compo-
nent, such as a human ventricular patch, has been challenging.
Herein, we report that ESC-derived ISL1+ human ventricular progen-
itors (HVPs) can recapitulate one of the earliest and most essential
steps of organogenesis: building of a functional ventricular heart
muscle in vivo, including controlled proliferation, followed by normal
growth, maturation, and self-assembly via a cell autonomous
pathway. We further demonstrate that transplantation of this HVP
population to the heart preserves function in injured myocardium.
RESULTS
Optimized Protocol Yields Efficient and Stepwise Ventricular
Differentiation In Vitro
Previous studies have documented a pivotal role for canonicalWnt sig-
nals indriving cardiacmyogenesis inESCs in in vitromodels17,18 aswell
as in ventricular muscle cell lineages in vivo.19 To maximize the gener-
ationof cardiomyocytes expressing the ventricularmarkermyosin light
chain 2v (MLC2v+) cardiomyocytes, we modified an existing two-step
protocol17 by using highly potent inhibitors of glycogen synthase ki-
nase 3 (GSK3) and porcupine (PORCN) at a lower concentration.
These slight modifications in protocol lead to the efficient and sequen-
tial conversion of hPSCs to HVPs (hPSCs-pan mesoderm-cardiac
mesoderm-islet ventricular progenitor) over 6 days (HVP protocol)
(Figure 1A). After 24-hr exposure to CHIR-98014, >99% of the hPSCs
expressed the pan-mesoderm marker Brachyury, as revealed by fluo-
rescence-activated cell sorting (FACS) (Figure 1B) and immunostain-
ing (Figure S1A). On day 3, more than 95% of the differentiated cells
expressed MESP1, a cardiac mesodermal marker (Figures 1C and
S1B). After 14 days, the HVP protocol resulted in >82% conversion
to ventricular cardiac myocytes, as illustrated by cardiac troponin T
(cTnT) and MLC2v flow cytometry (Figures 1D and 1E). ISL1 protein
expression began on day 4 and peaked at day 6, followed by NKX2.5 at
day 7, with its peak on day 11 (Figure 1F). Cardiac troponin I (cTnI)-
positive ventricularmyocyteswerenot induceduntil day11 (Figure1F).
Immunostaining of the day 6 HVPs showed substantial numbers of
ISL1+ cells (Figure S1F), and FACS analysis confirmed ISL1 expressionexpression by flow cytometry. (F) Protein expression was assessed by western blot a
synchronous HVP generation process. Gene expression profiles projected onto the first
colors. (H) Cluster analysis of gene expression profiles at different time points during HVP
hierarchically on the basis of similarity of their expression profiles. Expression pattern of
proportional to the relative gene induction (red) or repression (blue). ES, embryonic stem
CPC2, cardiac progenitor stages; CM1 and CM2, cardiomyocyte stages; Rnd1–4, un
with 5 candidate cell surface marker genes (JAG1, FZD4, FGFR3, LIFR, and TNFSF9) sa
that LIFR is highly expressed (>87%) on day 6 of differentiation. (K) Flow cytometry analy
illustrating leukaemia inhibitory factor (LIF) binding to heterodimers of LIF receptor and g
bind CT-1.
1646 Molecular Therapy Vol. 26 No 7 July 2018in 95.4%± 1.9% of cells at this stage (Figure S1C). In summary, we em-
ployed a modified HVP protocol, which enables production of ISL1+
HVPs efficiently within 6 days.
The sequential conversion of pluripotent stem cells to ISL1+ HVPs
was further illustrated by RNA sequencing (RNA-seq). Two batches
of RNA-seq (100- and 50-bp read length) were performed using the
Illumina Hiseq 2000 platform. Principal component analysis clus-
tered the cells by their developmental differentiation stage, effectively
reflecting the sequential steps of ventricular cell differentiation (Fig-
ures 1G and 1H). Downregulation of the pluripotency markers
OCT4, NANOG, and SOX2 during differentiation was followed by
the induction of the primitive streak-like genes T and MIXL1 by
24 hr and the upregulation of MESP1 on day 2 and day 3 (Figure S2).
Expression of the cardiac muscle markers TNNT2, TNNC1, MYL2,
MYL7, MYH6, MYH7, and IRX4 was detected at a later stage of dif-
ferentiation (after day 10; Figure S2). ISL1 mRNA was expressed as
early as day 4 and peaked on day 5, 1 day before its protein expression
reached its peak (Figure S1E). Western blot analysis (Figure 1F) and
double immunostaining (Figure S1F) of ISL1 and NKX2.5 confirmed
that ISL1 is an earlier developmental gene versus NKX2.5 gene in the
ISL1+ HVP lineage because purified HVPs uniformly expressed ISL1,
but remained largely negative for NKX2.5.
LIFR Surface Protein Marks Ventricular Progenitors on Day 6 of
Differentiation In Vitro
In order for the HVPs to ensure long-term cellular stability, it became
crucial to identify cell surface markers to define and purify the ven-
tricular progenitor population. The RNA-seq data collected at
sequential time points facilitated the potential to identify cell surface
markers that might be uniquely present during the initial onset of
HVP formation. We used the following 4 criteria to select candidate
genes: (1) high day 6/day 0 ratio; (2) correlates with ISL1 expression
pattern; (3) cell surface protein; and (4) highly expressed at day 6 (Fig-
ure 1I). Five candidates emerged, including the Notch pathway sur-
face ligand JAG1, Wnt signaling pathway receptor FZD4, FGF
signaling pathway receptor FGFR3, LIF receptor LIFR, and tumor ne-
crosis factor ligand TNFSF9. To confirm robust cell surface protein
expression, we performed live flow cytometry on day 6 HVPs using
conjugated antibodies against all five cell surface marker candidates
(Figure 1J). Of the 5 candidates, LIFR (Figure 1J) had the highest
protein expression on the cell surface, with LIFR+ cells comprising
87.4% of the total population. In addition, LIFR is only expressed at
a low level in ESCs, unlike other candidate cell surface markerst different time points during differentiation. (G) RNA-seq analysis of the rapid and
two principal components. Cells differentiated from different days are designated by
differentiation identifies stage-specific signature genes. These genes were clustered
each gene is displayed as a horizontal strip. The intensity of the red and blue color is
cells stage; MES, mesoderm stage; CMES, cardiac mesoderm stage; CPC1 and
classified groups. (I) Venn diagram displaying number of genes in each category,
tisfying all 4 categories. (J) Flow cytometry analysis of the 5 candidate genes showed
sis revealed that >86% of D6 cells co-express LIFR and ISL1. (L) Schematic diagram











(legend on next page)
www.moleculartherapy.org
Molecular Therapy Vol. 26 No 7 July 2018 1647







Ex Vivo Kidney Graft ES03 Day 15+ In Vitro
ES03 1+ Month Ex Vivo
Kidney Graft
AP upstroke time (ms) 128 ± 19 (n = 3) 128 ± 24 (n = 3) 129.7 ± 11.5 (n = 3) 143 ± 9 (n = 3) 105.0 ± 42.4 (n = 2)
AP 50% decay time (ms) 73.5 ± 4.1 (n = 3) 103.5 ± 5.5 (n = 3) 93.9 ± 18.5 (n = 3) 252 ± 41 (n = 3) 151.6 ± 2.8 (n = 2)
APD50 (ms) 202 ± 24 (n = 3) 232 ± 30 (n = 3) 223.6 ± 25.5 (n = 3) 395 ± 48 (n = 3) 256 ± 45 (n = 2)
APD90 (ms) 374 ± 66 (n = 3) 454 ± 10 (n = 3) 378 ± 32 (n = 3) 491 ± 91 (n = 3) 304 ± 1 (n = 2)
Conduction velocity
(cm/s)
2.08 ± 0.91 (n = 3) 2.41 ± 0.17 (n = 3) 2.19 ± 0.14 (n = 3) 3.35 ± 0.75 (n = 3) 1.89 ± 0.58 (n = 2)
Comparison of action potential parameters by optical mapping. The NKX2.5-GFP-labeled ESC line and ES03 cell line were employed for in vitro and ex vivo (i.e., kidney patch)
analyses. Measurements were made during 1-Hz pacing.
Molecular Therapy(Figure 1J), and previously has been shown to be the co-receptor of
the GP 130 cytokine cardiotrophin-1, which was originally isolated
by expression cloning during ESC in vitro cardiogenesis.20,21 Co-
staining of LIFR with ISL1 showed that the majority (>86%) of day
6 HVPs are LIFR and ISL1 co-positive (Figure 1J), demonstrating
LIFR as a robust cell surface marker for HVPs. Furthermore,
continued culturing of FACS-purified LIFR+ISL1+ HVPs to day 15
revealed robust beating (Movie S1) and expression of MLC2v (Fig-
ure S1I), demonstrating that LIFR+ISL1+ progenitors can give rise
to ventricular myocytes.
ISL1+ HVPs Differentiate into Cardiomyocytes Expressing
Ventricular Proteins and Exhibiting Mature and Uniform
Electrophysiological Properties
Next, we investigated the differentiation and maturation potential of
the HVPs. By day 9–12 of differentiation, HVPs form a uniform
wave-like beating monolayer in vitro that was NKX2.5+ (Movie S2).
As described previously, the majority of cells after 14 days of differen-
tiation were MLC2v and cTnT positive, indicating that most of the
cells have taken on a ventricular cardiomyocyte identity (Figures
1D and 1E). To determine the lineage potency of ISL1+ HVPs, a clonal
assay was performed, in which a single ISL1+ cell on day 6 of differ-
entiation was re-plated. During 3 weeks of differentiation, this cell
gave rise to cTnI and smooth muscle actin (SMA) double-positive
cells, a feature of immature cardiomyocytes, but not VE-cadherin-
positive endothelial cells, indicating that ISL1+ HVPs are ventricular
muscle progenitors (Figure S1J). HVPs differentiated as a population
to day 15+ also expressed various cardiac lineage markers, and the
majority of themwere positive for ventricular markerMLC2v, cardiac
troponin, and NKX2.5 (Figures 2A–2D); they were mostly negativeFigure 2. In Vitro Differentiation Potential of ISL1+ HVPs
(A–D) Day 15+ HVPs were analyzed for ventricular markers: (A) MLC2v and cTnT; (B) cT
and F) Optical recordings of spontaneous (E) and paced (F) day 18 HVP cells. Isochrom
asterisk represents the origin of point electrical stimulation. (G and H) Optical recordings
asterisk represents the origin of point electrical stimulation. (I and J) Patch clamp reco
potentials. (K) Whole cell patch clamp recordings of day 21 and day 40 HVP-derived
differences in various AP parameters between the two time points, suggesting that in vi
1 mM Ba2+. (M) Patch clamp recording comparison of If in ES03- and HES2-derived ve
(right) for If (n = 12). (N and O) Whole cell patch clamp recording of INa in ES03. (N) Repre
density I-V relationship (left) and steady-state activation/inactivation (right), n = 5. Histo
1648 Molecular Therapy Vol. 26 No 7 July 2018for MLC2a, whereas expression of HCN4 was completely absent
(Figures 2A, 2C, and 2D). Taken together, this protocol generates a
highly enriched pool of ISL1+ progenitors that differentiate into ven-
tricular cardiomyocytes. These highly enriched HVPs are distinct
from the previously reported KDR+ cells22 or multipotent ISL1+
cells,8,23 which can give rise to all three lineages of cardiovascular cells,
and are similar to the previously described rare, ISL1+murine ventric-
ular progenitors.24
We further characterized the maturation potential of these HVPs by
performing electrophysiology in vitro. We investigated the electrical
properties of the mature HVPs with optical mapping of action poten-
tial (AP) and calcium transients (CaTs), with a particular focus on
their ability to display electrical coupling. In vitro optical mapping
of day 6 HVPs revealed that there was no spontaneous or induced
propagation of the AP or CaT (n = 5; data not shown). By day 18+,
propagation of both the AP and CaT became readily apparent, both
spontaneously and following point stimulation (n = 5), suggestive
of network activity and electrical coupling (Figures 2E–2H and S3).
On day 6, the NKX2.5-GFP HVPs were GFP; patch clamping re-
vealed that all cells showed a depolarized resting membrane potential,
and upon stimulation, they were unable to fire APs upon stimulation
(n = 20; data not shown). By comparison, at later time points (day 21
and day 40), over 90% of cells were GFP+. GFP+ cells selected for
patch clamping showed polarized diastolic membrane potentials
and a ventricular-like AP (Figures 2I and 2J; n = 19). However, AP
configuration was comparable at day 21 and day 40 (Figure 2K;
Table 1). Similar results were obtained with the ES03-derived
HVPs, in which over 90% of day 21 and day 40 cells exhibited ventric-
ular-like APs (Table 1). Notably, these HVPs derived from both thenI; (C) pacemaker marker HCN4; and (D) atrial marker MLC2a. Scale bar, 20 mm. (E
e maps at 20-ms intervals show spontaneous action potential initiation. The white
of spontaneous (G) and paced (H) calcium transients in day 18 HVP cells. The white
rdings of day 15+ (I) and day 39+ (J) HVPs showed typical ventricular-like action
ventricular cardiomyocytes. Cultures demonstrated that there were no significant
tro, HVPs reached maturity by day 18. (L) Representative If traces in the presence of
ntricular cardiomyocytes. Steady-state I-V (left) and steady-state activation relations
sentative INa traces during activation (left) and inactivation (right). (O) Plots of peak INa
grams and traces are shown as mean ± SEM.
Table 2. Comparison of Calcium Transient Parameters between HVPs
during Ventriculogenesis In Vitro and In Vivo by Optical Mapping
Parameter
NKX2.5-GFP
Day 15+ In Vitro
NKX2.5-GFP
Day 30+ In Vitro
CaT upstroke time (ms) 266 ± 5 (n = 3) 234 ± 2 (n = 3)
CaT 50% decay time (ms) 186 ± 23 (n = 3) 255 ± 4 (n = 3)
CaT 50 (ms) 452 ± 12 (n = 3) 490 ± 2 (n = 3)
The NKX2.5-GFP-labeled ESC line was employed for in vitro and ex vivo (i.e., kidney
patch) analyses. All measurements made by optical mapping during 1-Hz pacing.
www.moleculartherapy.orgNKX2.5-GFP and the ES03 cell lines could be paced and exhibited an
APD90/APD50 ratio of <1.2; recapitulating the AP configuration of
native adult human ventricular myocytes (Figure 2K; Table 1).25–27
Calcium transients were comparable in day 15 and 30HVPs (Table 2),
with kinetics consistent with those of hPSC-derived cardiomyocytes
reported previously.28,29 We next investigated If, which is responsible
for cardiac pacemaking in immature and sinoatrial cardiomyocytes.30
Whole-cell voltage-clamp measurements (Figure 2L) showed that, in
comparison with cardiomyocytes differentiated from hESC (hES2)
using an embryoid body (EB)-based protocol,31 If current density
was reduced by half on day 21 HVPs (Figure 2M). The I-V plot
and steady-state activation/inactivation relationship of the sodium
current (INa) also showed characteristics typical of ventricular cardi-
omyocytes (Figures 2N and 2O). In addition, in vitro conduction of
both APs and CaTs was observed to be continuous and uniform, illus-
trating synchronous electrical coupling within the ventricular muscle
patch in vitro (Movies S3–S6). Furthermore, day 21 HVP-ventricular
cardiomyocytes showed responses to pharmacological agents charac-
teristic of native adult cardiomyocytes. Application of the b-adren-
ergic agonist isoproterenol increased conduction velocity, whereas
the parasympathetic agonist acetylcholine decreased it. Acetylcholine
also shortened action potential duration (APD), as expected. The
calcium channel blocker nifedipine also shortened APD and
decreased conduction velocity as in mature myocardium. Finally,
AP conduction in the presence of the non-specific gap junction inhib-
itor heptanol (0.5 mM) markedly reduced conduction velocity by
50% ± 23% (n = 3) without affecting AP amplitude, suggesting a
robust presence of gap junctions (Table S1). Together, these data indi-
cate that HVPs display a mature-like ventricular phenotype by as
early as day 19 in vitro.ISL1+ HVPs Form a Functionally Mature Graft on Kidney In Vivo
The ability to generate a large quantity of HVPs enabled the direct
analysis of their cell-autonomous potential to generate a ventricular
wall in vivo via transplantation under the kidney capsule (Figure 3A).
Sub-capsular transplantation of cells in the kidney is especially
optimal for its accessibility, and transplanted cells are well contained
under the renal capsule in a highly vascularized site. Furthermore, the
retroperitoneal location of the kidney, together with its separation
from other organs, is advantageous for imaging. Day 6 HVPs were
negatively magnetic-activated cell sorted (MACS) for the pluripotent
stem cell surface marker TRA-1-60 (<3% TRA-1-60+) to purify thepopulation. Three million TRA-1-60HVPs were transplanted under
the kidney capsule of immunocompromised NOD scid gamma
(NSG) mice (n = 30). 2 months after transplantation, a patch of
xeno tissue exceeding 0.6 cm in length and 0.2 cm in thickness was
found on the surface of the murine kidney (Figures 3A–3J). The
xeno tissue resembled a human ventricular muscle wall, characterized
by an organized array of cardiomyocytes. At the sub-cellular level,
electron microscopy revealed aligned sarcomeres, with distinct
organization of M- and Z-lines as well as A- and I-band domains
(Figure 3B). Immunohistochemistry further indicated sarcomeric
localization of a-actinin and actin typical of mature cardiomyocytes
(Figure 3C). In addition, membrane staining of cardiomyocytes
within the xeno tissue revealed an early T-tubule-like network that
was contiguous with the cell surface (Figure 3C). Although less dense
and organized than that present in adult ventricular myocytes, this
T-tubule-like network was reminiscent of the post-natal developing
heart.32 Consistent with a ventricular phenotype, the xeno tissue
exhibited uniform expression of both cTnT and the ventricular
markerMLC2v (Figure 3D).33 The ventricular wall was fully vascular-
ized, as assessed by expression of aSMA and VE-cadherin (Fig-
ure 3D), and the observation of red-blood-cell-containing capillaries
in electron microscopy (EM) micrographs (Figure 3B). Remarkably,
the human ventricular muscle wall was connected to the murine
host circulation, as indicated by red-lectin staining on the kidney
HVP graft after intravenous injection (Figure 3D). Surprisingly, the
HVPs secreted their own ECM, as demonstrated by the presence of
human fibronectin and laminin in the graft (Figure 3D). Very little
proliferation was observed within the ventricular muscle graft because
the majority of cells were both ISL1- and Ki67-negative (Figure 3D).
We next investigated the functionality of the in vivo kidney HVP
graft. Ex vivo optical mapping of 6- to 7-week-old kidney HVP grafts
revealed they were electrically responsive when stimulated (Figures
3F and S3). All of the 6+-week-old kidney HVP grafts (n = 5)
generated APs when electrically paced at various basic cycle lengths
(500–2,000 ms; Figure S3). In addition, they displayed an AP up-
stroke, decay time, and APD90/APD50 ratio (<1.4) comparable to
HVPs matured in vitro (Table 1), highlighting the remarkable ability
of day 6 HVP cells to self-assemble and differentiate into functional
cardiomyocytes in vivo. Optical mapping experiments also demon-
strated a rapid and continuous conduction of the AP across the
HVP grafts upon a point unipolar electrical stimulation. Further-
more, ultrasound imaging of in vivo 6+-week-old kidney HVP grafts
clearly illustrated the ability to contract (Movie S7). Beating of the
grafts occurred at a frequency of approximately 70 beats per minute.
Cross-sectional surface area of the graft contracted by 19% ± 4%
(n = 3) during a contraction cycle, returning to baseline during
relaxation (Figures 3H–3J).
ISL1+ HVPs Demonstrate a Unique Developmental Window for
Graft Formation
To assess whether day 6 HVPs represent a unique developmental
window to form a ventricular muscle graft, we transplanted late-stage
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www.moleculartherapy.orgthe kidney capsule (n = 4). At 6+ weeks post-transplantation, mice
with NKX2.5+ cells did not form any visible human muscle graft or
any other tissue, indicating the HVPs lose their cell-autonomous abil-
ity for in vivo ventriculogenesis following peak ISL1 expression (Fig-
ure 3G). Cells derived from an earlier time point in differentiation,
day 3, expressing MESP1 and thus representing cardiac mesoderm,
also failed to generate a homogeneous cardiac muscle graft on murine
kidneys; instead, heterogeneous tumor-like multi-tissue structures
were detected (n = 4; Figure 3G). Therefore, it seems that the unique
developmental properties of day 6 HVPs allow their engraftment and
assemble into a human ventricular muscle xeno-graft in vivo.
ISL1+ HVPs Form a Stable, Congruent Graft on Uninjured,
Healthy Murine Heart
To determine if immature HVPs can engraft into an uninjured heart,
two million purified (negatively sorted for TRA-1-60) NKX2.5-GFP-
labeled HVPs were injected intra-myocardially into the hearts of NSG
mice (n = 25, Figure 3A). Hearts were harvested 2 and 8 months after
transplantation (data not shown for 2 months). Upon sectioning,
GFP+ cells were found in the myocardium (Figures 4A and 4B).
HVP heart graft patches uniformly expressed NKX2.5 (Figures 4A
and 4B), and were also positive for the cardiac ventricular marker
MLC2v. Studies of HVP cardiac grafts 8 months (n = 4) post-trans-
plantation documented the long-term stability of relatively pure,
uniform MLC2v+ ventricular muscle graft that was negative for
MLC2a, HCN4, and ISL1 staining (Figure 4B), without formation
of teratomas or other non-ventricular human cell types. The
8-month-old graft remained vastly integrated within the host
myocardium because connexin 43 (CX43)-positive cells were present
throughout the graft (Figure 4B). The ventricular graft patch was
vascularized, as assessed by expression of CD31 (Figure 4B). Taken
together, these studies suggest that in the normal heart, in the absence
of an endogenous niche (created by cardiac injury), the HVPs can
engraft, self-assemble, differentiate, vascularize, and acquire features
of maturation while generating a stable, long-term, homogeneous
ventricular muscle graft in vivo.
ISL1+ HVPs Improve Local and Global Functions after MI
To assess their regenerative capacity, we injected 2 million HVPs
intra-myocardially into NSG mice immediately after myocardialFigure 3. In Vivo Transplantation of HVPs under Renal Capsule
(A) Schematic illustration of HVP generation, differentiation, and transplantation. HVPs w
site marked with squares); photos illustrate where the HVP graft was formed 2months af
in the kidney capsule revealedmature ultra-structure, including organized and aligned sa
apparent were desmosomes, mitochondria, myofilament bundles (middle panel), and
rescence images further demonstrate sarcomeric organization within HVP grafts, wit
Membrane staining (WGA) revealed the presence of developing T-tubules (middle panels
the HVP kidney patch, with antibodies against MLC2a, MLC2v, cTnT, aSMA, ISL1, lamin
was injected via the tail vein, illustrating a direct connection of the HVP kidney patch wi
patch was harvested for ex vivo optical mapping and observed under brightfield (E) to be
engraftment occurred at day 6 of differentiation; day 3 mesodermal MESP1+ cells resulte
muscle graft patch (n = 4). (H and I) Cross-sectional area of a 6+-week-old HVP kidney
systolic phase; I), respectively, as imaged by ultrasound. (J) Measured cross-sectionalinfarction (MI) induced by left anterior descending (LAD) artery liga-
tion. The injection was targeted to the infarction border zone (n = 5).
The results were compared with a control group (n = 5), i.e., mice with
LAD ligation, which received placebo treatment (cell culture medium
without cells). After a 2-month follow-up, MRI was performed to
evaluate left ventricular volumes, wall thickness, and global and local
function (Figures 4F and 4G; Movies S8 and S9). When compared to
the placebo group, the HVP-treated group showed improved ejection
fraction (p = 0.0079) and augmented wall thickening at the infarction
site (p = 0.0159). In addition, left-ventricular end-systolic volume was
smaller in the HVP-treated group (p = 0.0159), consistent with
improved contractility.
The injected hearts were collected for histological analysis. The graft
was observed to be largely ventricular MLC2v+ (Figures 4D and S4),
negative for non-ventricular heart markers such as HCN4 (Figure 4D)
and MLC2a (Figure 4D), and negative for the progenitor makers ISL1
and Ki67 (Figure 4D). The ventricular grafts were integrated into the
host myocardium, as shown by the presence of CX43 (Figure 4D).
Furthermore, the graft contained ECM, as indicated by robust expres-
sion of laminin and fibronectin (Figure 4D). Higher resolution
fluorescence imaging of the border zone revealed cardiomyocytes
containing human mitochondria and well-organized sarcomeres
embedded within the fibrous tissue (Figure 4E). This observation
suggests that well-differentiated ventricular cardiomyocytes engrafted
within the border zone actively contribute to the enhanced
contractility observed in post-infarction hearts following HVP
transplantation.
DISCUSSION
The human ventricular myocardium has a limited capacity for regen-
eration, most of which is lost after 10 years of age.4 As such, new
strategies to generate heart muscle via repair, regeneration, and tissue
engineering approaches during cardiac injury have been a subject of
intense investigation in regenerative biology and medicine. The
assumption is that given the complex 3D structure of solid organs,
achieving coordinated parenchymal cell proliferation, vasculariza-
tion, and matrix formation would ultimately require the addition of
vascular cells and/or conduits, biomaterials, and/or a de-cellularized
matrix to form a functional tissue.34 However, the complexity ofere injected under the kidney capsule or intra-myocardially into the heart (injection
ter transplantation, when it was recovered. (B) Electron microscopy of the HVP patch
rcomeres, with well-defined Z-line, M-line, A-band, and I-band (left micrograph). Also
capillaries containing red blood cells (right panel). (C) High-resolution immunofluo-
h transverse orientation of a-actinin at z-lines and actin staining between z-lines.
, high magnification of indicated region at right). (D) Immunofluorescence staining of
in, HCN4, human fibronectin, VE-cadherin, and Ki67. Scale bar, 200 mm. Red lectin
th the host venous system. Scale bar, 50 mm. (E and F) A 6+-week-old HVP kidney
electrically responsive to stimulation (F). (G) A unique developmental window for HVP
d in teratomas, and day 10 late NKX2.5+ heart precursors failed to form a ventricular
graft patch during relaxation (i.e., diastolic phase; H) and maximal contraction (i.e.,
area of the graft patch during diastole and systole.
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late this to clinical practice.35 Although hPSCs hold great promise, to
date it has not been possible to build a pure, vascularized functional
3D human ventricular muscle patch in vivo in a mammalian system
without the addition or support of scaffolds.36 Thus far, the most
advanced studies designed to generate in vivo heart patches and/or
grafts in vivo have been based on using partially purified, differenti-
ated pools of heart cells (atrial, ventricular, pacemaker, and other).
However, these studies have faced limitations regarding the maturity
of the subsequent heart tissue, relative purity of tissue for ventricular
muscle, electrical heterogeneity from atrial and pacemaker cell types,
long-term stability, and requirement of matrices/scaffolds or suturing
into the myocardium to allow grafting. At the same time, the use of
heart progenitors as a starting material has been hampered by the
requirement for the absence of pluripotent stem cells and other pre-
cursors, and the tendency for the progenitor cells to be multipotent,
leading to heterogeneity of the tissue construct. Furthermore, it has
been unclear whether these cells would go on to exit the progenitor
state and display controlled growth, assume a rod shaped conforma-
tion with sarcomeric organization, and expand in size without
continuing to proliferate.
Herein, we identified a cell population positive for the cardiac progen-
itor marker ISL1 and able both to form a large ventricular muscle
patch on the murine kidney in a completely non-native environment
and engraft into uninjured and injured murine heart after intra-
myocardial injections. The ability to generate a large quantity of
HVPs from a renewable source of either human ES or iPS cell lines
represents a new approach to the generation of functional ventricular
muscle in the setting of advanced heart failure. As reported in our
current study, one of the key aspects of HVP self-assembly into a
ventricular-like wall in vivo is its developmental time window, which
coincides with peak ISL1 expression. We show that early cardiogenic
mesoderm will not be coerced toward ventricular muscle, whereas
immature cardiomyocytes lack the ability to form a ventricular
muscle wall in a cell autonomous manner. This raises the biological
question of what are the unique properties that enable HVPs to
form a vascularized 3D xenograft on a kidney. Within the kidney-
grown ventricular graft, we found expression of laminin, an ECM
component. Interestingly, laminin has high gene expression levels
on day 7 of cardiomyocyte differentiation in vitro (Figure S1G),
thus implying that transplanted, differentiating HVPs are able to pro-Figure 4. In Vivo Transplantation of HVPs into Healthy and Injured Hearts
(A) White dashed box denotes the location of the HVP graft 8 months following intramyo
HVP ventricular grafts in the heart expressed NKX2.5-GFP (green), MLC2v, connexin 43
and ISL1. CD31 was only present outside the graft. (C) The white dashed box identifies t
HVPs into the border zone of MI hearts. Red asterisks denote infarction site. (D) Im
co-expressed NKX2.5-GFP (green), connexin 43, human nuclei, MLC2v, MHY11, huma
HCN4 staining was not observed. Endothelial marker CD31 was detected in close proxi
grafts demonstrated engrafted, differentiated cardiomyocytes of human origin, with well
[red], and F-actin [orange]). (F) MRI assessment of post-MI hearts 2 months followin
with placebo. Representative short axis images show wall thickness at the site of induce
SD of wall thickening, ejection fraction, and volume during end diastole (EDV) and endduce their own matrix in vivo. Cardiac laminins are known to be
required in normal cardiovascular development and function.37
Furthermore, recent studies38 have demonstrated the important
contribution of ECM in cardiac differentiation and suggest that
specific matrix components can regulate cardiomyocyte maturation.
Because HVPs do not differentiate into endothelial cells in vitro,
the vasculature in the HVP kidney graft in vivo is most likely derived
from the host and triggered via paracrine cues. In this regard, para-
crine factors such as VEGF, a potent factor for vascular generation
and regeneration,39 are highly expressed from the HVP stage onward
(Figure S1H). To complete the characteristics of functionality in the
tissue generated from HVPs in vivo, a well-organized sarcomeric
structure and a network of developing T-tubule-like structures were
observed, a key parameter of maturation that has heretofore not
been reported in a stem-cell-derived heart tissue construct in vivo.
When the engraftment of HVPs into an uninjured murine heart was
observed, we proceeded to investigate their potential as a therapeutic
agent in an MI model. Interestingly, HVPs were able to locate a niche
in the border zone of infarcted murine myocardium and assist in pre-
serving the left ventricular function after infarction to such an extent
that ejection fraction is preserved toward normal levels. The trans-
planted immature progenitors matured in vivo, lost their progenitor
state, and adapted the expression profile of adult ventricular cardio-
myocytes. Given the modest functional improvements achieved
with transplantation of more mature cardiac cells,40,41 the use of
HVPs for infarction therapy might provide several advantages: the
uniqueness of this study lies in the dynamic progenitor state of the
cells transplanted, putatively enabling, better engraftment, in vivo
maturation, and thus potential for coherent tissue integration.
HVPs may exert their beneficial effects via multiple different routes,
not merely by addition of new exogenous muscle. This notion is
supported by the fact that the infarcted muscle region is only partially
replaced by the human HVP-derived ventricular muscle, yet the
preservation of function is nearly complete, as assessed by the near
normal ejection fraction and preserved wall thickening and function.
One intriguing possibility is that paracrine signaling augments
growth, form, and function of neighboring viable endogenous cardiac
muscle. Progenitor cells are known to secrete beneficial factors
important for, e.g., stress endurance.42,43 Defining these factors and
combining them within the HVPs via modified RNA (modRNA)
technology will become of interest to further improve the maturation,cardial injection into a healthy heart. (B) Immunofluorescence staining showed that
, and MHY11; a minority of cells co-expressed MLC2a and was negative for HCN4
he localization and the engraftment of the xeno tissue 2 months after injection of the
munofluorescence staining showed that HVP ventricular grafts in post-MI hearts
n fibronectin, and laminin. A minority of cells was positive for ki67; MLC2a, ISL1, and
mity to the HVP graft. (E) High-resolution imaging of the border zone of post-MI HVP
-organized sarcomeres (stains of cell membrane [WGA, green], human mitochondria
g HVP transplantation showed improved global and local function in comparison
d infarction (arrows). LV, left ventricle; RV, right ventricle. (G) Mean measurements ±
systole (ESV). *p < 0.05; **p < 0.01; n/s, not significant.
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Molecular Therapysize, and function of the HVP-derived heart muscle graft and their
potential application to heart failure.
Herein, we identified LIFR as a potential positive selection marker for
HVPs. Human ESCs do not require LIF in culture and LIFR is ex-
pressed only in low levels,44 unlike its murine counterpart, in which
LIF is an important transducer of pluripotency.45 Additionally, the
LIFR-GP130 heterodimer serves as the receptor of cardiotrophin-1
(CT-1), a cytokine that was initially isolated from a murine ESC
model of in vitro cardiogenesis, and which has a direct effect on
cardiomyocyte survival and function (Figure 1L).32 It will be of
interest to determine the precise role of cardiotrophin-1 signaling
pathways in the self-assembly and maturation of HVPs during in vivo
human ventriculogenesis.
Our study also presents new means for cardiovascular drug develop-
ment and discovery. To date, some hPSC-based models of cardiac
disease have had the limitation of being in vitro based or with poor
electrical integration of grafts with a host.2,30 Furthermore, the imma-
ture properties of the cells limit their utility and fidelity in the adult
heart. Our present work has established a unique degree of matura-
tion of stem-cell-derived cardiomyocytes, with the appearance of
organized sarcomeres and developing T-tubule-like structures, events
known to occur well into the post-natal stages of ventricular develop-
ment.30,32 Functionally, our electrophysiology studies demonstrated
that HVP-derived cardiomyocytes successfully recapitulate features
of native human ventricular cells, with an APD90/APD50 ratio of
roughly 1.2, one of the key characteristics of a mature human ventric-
ular cell. Moreover, whole cell patch clamping experiments with
HVP-derived ventricular cardiomyocytes showed that If is consider-
ably lower compared to cells differentiated by another protocol,
further indication of HVP ventricular myocyte maturity.46 HVPs
differentiated in vitro also showed close cell-cell association, as exem-
plified by continuous conduction of both AP and CaT signals. Indeed,
the development of gap junctions was demonstrated by the observa-
tion of marked decrease in conduction velocity upon the administra-
tion of a gap junction inhibitor. The integration of the HVP graft with
the host was further exemplified with the presence of robust CX43
staining in both healthy and post-MI hearts. To our knowledge, no
other studies have shown successful engraftment of HVPs within a
healthy adult murine heart at such a late stage (8 months of follow-
up). Although the current study documents the cell autonomous
nature of ventriculogenesis from human HVPs, it is clear that
additional paracrine cues will be required to enhance the function,
vascularization, and maturation of the functional ventricular graft
patch. Toward this goal, we recently have identified several paracrine
cues that can expand and promote the differentiation of the HVPs via
screening with a paracrine factor modRNA library.42
As the field has become saturated with studies developing differenti-
ated cardiomyocytes for cell therapy purposes, progenitor-stage cells
are gaining popularity as a vehicle for therapy. Recent first-in-human
clinical studies have supported the safety of in vivo transplantation of
enriched populations of multipotent ISL1+ heart progenitors derived1654 Molecular Therapy Vol. 26 No 7 July 2018from human ESCs.47 These cells appear to be much earlier in the
process of mesodermal differentiation, because they co-express
OCT4, a pluripotency gene, and also contain ISL1+ neural progeni-
tors. Although these cells seem unable to form a large-scale ventricu-
lar tissue in the human studies, there was evidence of ventricular
progenitor activity in in vivo grafting studies in non-human primate
(NHP) models post-MI. In another study by Takeda et al.,48 CD82
was reported to be a potential marker for a cell population of cardio-
myocyte-fated progenitors (CFPs) isolated from the KDR+PDGFRa+
subpopulation in iPSCs.41 Both HVPs reported in the current study
and CFPs were able to survive in the sub-renal space in mice and
infarcted murine hearts in vivo. In addition to this, we show that
HVPs were able to reverse MI-induced dysfunction. Furthermore,
HVPs give rise to a highly enriched MLC2v+ ventricular population.
It remains to be seen whether CFPs produce a specific or a mixture of
cardiomyocyte subpopulation, and whether they would have a thera-
peutic effect on cardiac function. We compared HVPs and the CFPs
by examining CD82 expression in our RNA-sequencing dataset and
found that CD82 is expressed at very low levels across all time points.
This strongly suggests HVPs and CFPs are distinct cardiac progeni-
tors and may have different important functional differences. This
difference may be due to (1) small changes in the protocol that can
have a direct effect on ventricular specification and/or (2) transplan-
tation of day 5 cells is possibly too early (before progenitors’ commit-
ment to ventricular lineage).
As reported here, our HVP population was able to reverse
MI-induced dysfunction; the hypothesis is that this committed ven-
tricular progenitor population may prove less arrhythmogenic than
a mixed population of cardiomyocytes, a very important feature for
clinical trials. However, this remains to be confirmed in large animal
model systems because themouse fails to allow this level of resolution.
Further purification of HVPs, such as identification of a positive
marker, which can be MAC sorted, will be of critical importance in
order to optimize large-scale cell production and move toward clin-
ical trials in humans. Moreover, as discussed above, controlling the
graft dynamics via exposure to paracrine factors with, e.g., mod-
RNAs,4 will ultimately be of interest to examine the therapeutic
potential of purified HVPs. In particular, can the size, scale, and
topographical distribution of the HVP graft be enhanced by transfec-
tion of modRNAs encoding specific paracrine factors to improve
expansion and differentiation prior to implantation and/or after
initial in vivo graft formation? Nevertheless, all these recent studies




hPSCs (ES03 and NKX2.5 eGFP) were maintained on Matrigel (BD
Biosciences, Germany) coated plates in E8 medium (GIBCO, USA)
according to previously published methods.49,50 Fresh E8 medium
was replaced daily. Once the cells reached 80%–90% confluence,
they were dissociated into single cells with Accutase (Innovative
Cell Technologies, USA) at 37C for 5 min and passaged 1:6–1:9
www.moleculartherapy.orgonto new Matrigel-coated 6-well plates in E8 supplemented with
5 mM ROCK inhibitor Y-27632 (STEMCELL Technologies, Canada)
for the first 24 hr. The ES03 cell line was obtained from Wicell
Research Institute (Madison, WI, USA), and the NKX2.5 eGFP line
was a kind gift of Dr. David Elliott (MCRI, Australia). In brief, se-
quences encoding enhanced GFP (eGFP) were introduced into the
NKX2.5 locus by homologous recombination.51 All NKX2.5 eGFP
clones contained a single integration event and expressed markers
of undifferentiated hESCs. The cell lines presented capacity to form
teratomas in vivo in an undifferentiated state, an ESC property. No
additional cell line validations were performed. These lines were
tested negative for mycoplasma.
HVP Generation Protocol
hPSCs maintained on a Matrigel-coated surface in E8 were dissoci-
ated into single cells with Accutase (Innovative Cell Technologies)
at 37C for 5 min and 2 days prior to differentiation are seeded
into an evenly distributed monolayer onto a Matrigel-coated cell
culture dish at 100,000–200,000 cell/cm2 (1 million cells per well in
a 12-well plate) in E8 supplemented with 5 mM ROCK inhibitor
Y-27632 (day 2) (STEMCELL Technologies) for 24 hr. On
day 1, media is changed and cells are cultured in E8.
On day 0, they are fully confluent, and differentiation is initiated by
removing E8 medium and adding RPMI/B27 without insulin
(RPMI/B27-ins; GIBCO) and containing 1 mM GSK3 inhibitor
CHIR 98014 (Selleckchem, USA). Media are changed to RPMI/
B27-ins 24 hr after.
On day 3, half of the medium was changed to the RPMI/B27-ins me-
dium containing 2 mM Wnt-C59 (Selleckchem), which was then
completely removed during the medium change on day 5. On
day 6, cells were dissociated into single cells and purified with
Tra-1-60 or LIFR antibody.
HVP Production
Using the cell culture methods described above, 1 million cells were
seeded per well in a 12-well plate on day 2 for differentiation. On
day 6, approximately 4 million HVPs were collected per well (approx-
imately 48 million cells per plate); on average, eight to ten 12-well
plates with HVPs from the same batch were cultured and collected
at the same time for sorting and transplantation, as described below.
RNA-Seq Library Construction
RNA was isolated (RNeasy Mini kit, QIAGEN, Germany), quantified
(Qubit RNA Assay Kit, Life Technologies, USA), and quality
controlled (BioAnalyzer 2100, Agilent, USA). RNA (800 ng) from
each sample was used as input for the Illumina TruSeqmRNA Sample
Prep Kit v2 (Illumina, USA), and sequencing libraries were created
according to the manufacturer’s protocol. Briefly, poly-A-containing
mRNAmolecules were purified using poly-T oligo-attached magnetic
beads. Following purification, the mRNA was fragmented and copied
into first strand complementary DNA using random primers and
reverse transcriptase. Second strand cDNA synthesis was then doneusing DNA polymerase I and RNase H. The cDNA was ligated to
adapters and enriched with PCR to create the final cDNA library.
The library was pooled and sequenced on a HiSeq 2000 (Illumina,
USA) instrument per the manufacturer’s instructions.
RNA-Seq Data Processing
The RNA-seq reads were trimmed and mapped to the hg19 reference
using Tophat 2. On average, approximately 23 million reads were
generated per sample, and 76% of these reads were uniquely mapped.
Expression levels for each gene were quantified using the python
script rpkmforgenes and annotated using RefSeq. Genes without at
least one sample with at least ten reads were removed from the
analysis. Principle Component Analysis and heatmaps were con-
structed using the R and Gene-E, respectively.
Animals
For all animal experiments, we used immunodeficient mice,
NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (Taconic, Copenhagen), all
male, aged between 2 and 4 months at the time of experiment start.
The animals’ care was in accordance with the institutional guidelines
of the Karolinska Institutet, and all animal experiments were
approved by the local ethics committee (Stockholm, Sweden) in
accordance with the Animal Protection Law, the Animal Protection
Regulation, and the Regulation of the Swedish National Board for
Laboratory Animals.
Transplantation
Two to three million purified HVPs were collected into an Eppendorf
tube. Cells were spun down, and the supernatant was discarded.
Contents of each tube of cells were transplanted under the kidney
capsule (3 million cells) or intra-myocardially injected into the heart
(2 million cells) of the immunodeficient mice. We followed a previ-
ously described protocol for kidney transplantation52 under analgesia
and inhalation anesthesia with 2%–2.5% isoflurane. Transplantations
of cells in different differentiation stages were performed without
blinding and randomization. Intramyocardial injections into the
mid-anterior left ventricular wall were performed for intubated and
machine-ventilated mice via left thoracotomy under analgesia and
isoflurane anesthesia of 2%–2.5%. Engrafted kidneys or hearts were
harvested at various time intervals for histological and physiological
analysis.
Flow Cytometry
Cells were dissociated into single cells with Accutase for 5 min and
filtered through a 40-mm cell strainer before staining with Anti-
TRA-1-60 MicroBeads (Miltenyi Biotec, Germany) according to the
manufacturer’s instructions. Cells were negatively sorted with an
autoMACS Pro Separator (Miltenyi Biotec, Germany), and the nega-
tive fraction was negatively sorted again. A fraction of the cells were
stained with anti-human TRA-1-60 antibody conjugated with Alexa
Fluor 488 (STEMCELL Technologies, Canada) according to the man-
ufacturer’s instructions, and analyzed by flow cytometry using a
FACSCaliber. Batches with <3% TRA-1-60-positive cells were used
for transplantation purposes. LIFR is a cell surface marker, andMolecular Therapy Vol. 26 No 7 July 2018 1655
Molecular Therapystainings were performed on live cells. Cells were suspended in PBS/
0.5% BSA/2 mM EDTA (flow buffer) before staining with allophyco-
cyanin (APC)-conjugated anti-human LIFR alpha antibody (R&D
Systems clone #32953, MAB249, USA) according to the manufac-
turer’s instructions. For intracellular stainings, cells were fixed with
4% PFA for 20 min, and then permeabilised with 0.1% Triton
X-100/PBS for 2  5 min before staining with primary antibodies
in 10% goat serum, 1% BSA, and 0.1% saponin (blocking buffer) in
PBS overnight in 4C. Cells were then washed twice in flow buffer
before staining with secondary antibodies diluted in blocking buffer.
ISL1 (DSHB, 39.3F7, USA), cTnT (Thermo Fisher Scientific, MS-
295-P1, USA), and MLC2v (Proteintech, 10906-1-AP, Germany)
primary antibodies were used. Alexa fluorophore secondary
antibodies (Thermo Fisher Scientific, USA) were used at a concentra-
tion of 1:1,000. Flow cytometry and FACS were performed on a
FACSCalibur and a FACSAria Fusion flow cytometer, respectively.
Immunostaining
Cells were fixed with 4% paraformaldehyde for 15 min at room tem-
perature and then stained with primary and secondary antibodies in
PBS plus 0.4% Triton X-100 and 10% donkey serum. Tissue samples
were fixed with 4% formaldehyde overnight at 4C. After cryoprotec-
tion with sucrose, samples were embedded in OCT and sectioned at
8-mm thickness with a cryostat. Tissue sections were subsequently
stained with various antibodies against aSMA (Thermo Scientific,
14-9760-82, USA); Brachyury (R&D Systems, AF2085, USA); CD31
(Cell Signaling Technology, mab 3528, USA); cTnI (Abcam,
ab47003, UK); connexin 43 (Abcam, ab11370, UK); cTnT (Thermo
Scientific, MS-295-P1, USA); GFP (Abcam, ab13970, UK); HCN4
(R&D Systems, MAB8138, USA); human fibronectin (R&D Systems,
AF1918, USA); ISL1 (DSHB, 39.3F7, USA); Ki67 (BD Pharmingen,
550609, USA); human mitochondria (Millipore, mab1273, USA);
laminin (DSHB, 2E8, USA); Mesp1 (Abcam, ab77013, UK); MLC2v
(Proteintech, 10906-1-AP); MLC2a (Synaptic Systems, 311-011);
MYH11 (Sigma, HPA015310, USA); and VE-cadherin (R&D
Systems, USA). Nuclei were stained with Gold Anti-Fade Reagent
with DAPI (Invitrogen, USA). An epifluorescence microscope and
a confocal microscope (ZEISS, LSM 700) were used for imaging
analysis.
For super-resolution imaging, sections were treated with consecutive
steps for chemical fixation (4% formaldehyde in 0.1 mol/L HEPES
buffer, 10 min), quenching (PBS + 100 mmol/L glycine, 10 min), per-
meabilization (PBS + 0.03% Triton X-100, 10 min), and blocking
(NaCl 150 mmol/L, Na3 citrate 17.5 mmol/L, 5% goat serum, 3%
BSA, and 0.02% NaN3, 2 hr). PBS washing was performed in between
each step. The sections were then incubated overnight with 1/100
diluted primary antibody against a-actinin (sc-7454, Santa Cruz) or
human mitochondria (MAB1273, Sigma) in low blocking buffer
containing 150 mmol/L NaCl, 17.5 mmol/L Na3 citrate, 2% goat
serum, 1% BSA, and 0.02% NaN3 at 4C. The following day, cells
were washed with PBS and incubated with 1/200 diluted secondary
antibody: Atto 488 Anti-Mouse (62197, Sigma) or Alexa Fluor 680
conjugated goat-anti-mouse secondary antibody (A32729, Thermo1656 Molecular Therapy Vol. 26 No 7 July 2018Fisher Scientific). Actin filaments were stained with 1/500 diluted
Alexa Fluor 546 Phalloidin (A22283, Thermo Fisher Scientific),
whereas surface membrane and T-tubules were labeled with
20 mg/mL wheat germ agglutinin (WGA) and Alexa Fluor 488 conju-
gate (W11261, Thermo Fisher Scientific) in low blocking buffer for
2 hr. Sections were washed and sealed beneath a coverslip with
SlowFade Diamond Antifade Mountant with DAPI (S36963, Thermo
Fisher Scientific). Imaging was performed on a ZEISS LSM 800 with
Airyscan using the Airyscan super-resolution mode.
Electron Microscopy
Following perfusion fixation (as described for immunostaining), tis-
sue was treated with 2% osmium tetroxide for 2 hr. Dehydration
was then performed with stepwise increases in ethanol concentration
(50%, 70%, 90%, and 100%, 30 min each step, room temperature), fol-
lowed by treatment with 2% uranyl acetate in ethanol (30 min) and
acetone (2 X 20 min). Infiltration was attained with acetone/EPON
treatment in a progressively decreasing ratio (2:1 for 60 min, 1:1 over-
night, and 1:2 for 60 min). Embedding was performed in pure EPON
(5 to 6 hr) with Eppendorf tubes as molds. Polymerization was per-
formed overnight at 60C. Semi-thin sections were cut and stained
with Toluidin Blue in order to localize structures of interest for mak-
ing ultrathin sections. EPON blocks were then trimmed with respect
to the structure of interest, and ultrathin sections were cut on an
ultramicrotome (Leica, UPC6), followed by staining with 4% uranyl
acetate in 40% ethanol and Reynholds lead citrate. Finally, the ultra-
thin sections were examined in a transmission electron microscope
(Tecnai Spirit Biotwin, FEI).
Western Blot Analysis
Cells were lysed in M-PER Mammalian Protein Extraction Reagent
(Pierce Thermo Fisher Scientific, USA) in the presence of Halt Prote-
ase and Phosphatase Inhibitor Cocktail (Pierce Thermo Fisher, USA).
Proteins were separated by 10% Tris-Glycine SDS/PAGE (Invitrogen,
USA) under denaturing conditions and transferred to a nitrocellulose
membrane. After blocking with 5% dried milk in TBST, the mem-
brane was incubated with primary antibody overnight at 4C. The
membrane was then washed, incubated with an anti-mouse/rabbit
peroxidase-conjugated secondary antibody at room temperature for
1 hr, and developed by SuperSignal chemiluminescence (Pierce
Thermo Fisher, USA).
Electrophysiology
Patch clamp: Electrophysiological experiments were performed using
the whole-cell patch-clamp technique as previously described.53,54 To
profile chamber-specific subtypes of HVP cells, action potentials of
the cardiomyocytes were randomly probed at 37C. Axopatch 200B
amplifier, Digidata 1322A, and pClamp software (Axon Instru-
ments/Molecular Devices, USA) were used. The internal solution
contained (in mM) 110 K+ aspartate, 20 KCl, 1 MgCl2, 0.1 Na-
GTP, 5 Mg-ATP, 5 Na2-phospocreatine, 1 EGTA, and 10 HEPES,
pH adjusted to 7.3 with KOH. The external Tyrode’s bath solution
consisted of (mM) 140 NaCl, 5 KCl, 1 CaCl2, 1 MgCl2, 10 glucose,
and 10 HEPES, pH adjusted to 7.4 with NaOH. For INa recording,
www.moleculartherapy.orgthe internal solution contained (in mM) 135 CsCl, 10 NaCl, 2 CaCl2,
5 EGTA, 10 HEPES, and 5 MgATP, pH adjusted to 7.2 with CsOH.
The external solution contained (in mM) 25 NaCl, 135 CsCl,
5 CaCl2, 1 MgCl2, 10 glucose, 10 HEPES, and 0.001 Nifedipine, pH
adjusted to 7.4 with CsOH. All reagents are analytical grade
(Sigma-Aldrich, USA). The HVP cells were categorized into nodal,
atrial, or ventricular like according to the standard AP parameters,
as others have previously described.53,54
Optical mapping: Action potential in HVP cells was measured by
loading the cells with the voltage-sensitive dye, Di-8-ANEPPS
(5 mmol/L, Invitrogen, USA), for 30 min at 37C in DMEM/F12,
followed by imaging with a CMOS-based camera (MiCAMULTIMA,
SciMedia USA, CA, USA) in Tyrode’s solution containing (in
mmol/L) 140 NaCl, 5 KCl, 1 CaCl2, 1 MgCl2, 10 glucose, and
10 HEPES, pH adjusted to 7.4 with NaOH. Blebbistatin (50 mmol/L)
was added and incubated for 15 min before measurements to avoid
motion artifacts.
Intracellular Ca2+ transients were analyzed by loading the HVP cells
with X-Rhod-1 (2 mmol/L Invitrogen) for 30 min at 37C in DMEM/
F12, followed by imaging with a CMOS-based camera (MiCAM
ULTIMA, SciMedia USA, CA, USA) in Tyrode’s solution. Blebbista-
tin (50 mmol/L) was added and incubated for 15 min before measure-
ments. Electrical pacing was induced by a unipolar point electrode
placed perpendicular to the surface HVP ventricular cardiomyocytes.
Pacing was performed at 1 Hz, with a 10-V stimulus and 10 ms in
duration.
Ultrasound Imaging
Ultrasound scanning was performed on a VisualSonics Vevo 2100
Imaging Station (VisualSonics, Canada). Mice were anesthetized
using 1.5% isoflurane, with air at a flow of 2 L/min. Hair was removed
over areas of interest using a depilatory cream. Ultrasound gel (Parker
Lab, USA) was applied over the region of interest. Electrocardiog-
raphy (ECG), respiration, and body temperature were monitored
during image acquisition. To eliminate respiration artifacts from
cine imaging, respiratory gating was applied.
MI Model
MI was induced by permanent LAD artery ligation for intubated
and machine-ventilated immunodeficient mice. The surgery was
via left thoracotomy under analgesia and isoflurane anesthesia of
2%–2.5%, and a suture was placed around LAD with 8-0 un-absorb-
able Ethilon monofilament thread (Ethicon, USA) in the middle part
of the artery’s course from base to apex. Two million HVPs (N = 5)
or an equivalent volume of placebo (cell culture medium without
cells; N = 5) were injected in a random order decided by the inves-
tigator before surgeries; no blinding was performed. Injections
were performed intramyocardially immediately after LAD ligation
into the developing infarction border zone close to the suture using
the same techniques as described previously under “Transplanta-
tion.” Engrafted hearts were harvested at 2 months for histological
analysis.MRI
The scanning was performed at the Department of Comparative
Medicine/Karolinska Experimental Research and Imaging Centre
at Karolinska University Hospital, Solna, Sweden. Prior to organ
harvest, in vivo functional imaging was performed for MI-induced
mice at a 2-month time point. For imaging, anesthesia was induced
using 3% isoflurane in a 20:80 mixture of oxygen and air, before be-
ing positioned in a magnetic resonance (MR) compatible bed, in
which the isoflurane was supplied through a nose cone. The isoflur-
ane level was 1%–2.5%, adjusted to maintain the respiration fre-
quency between 50 and 100 breaths per minute. An MR-compatible
physiology monitoring system was used (SA-instruments, Stony
Brook, NY, USA), with respiration sensor, ECG, and body temper-
ature providing feedback control of the warm air heating system
maintaining the body temperature at 37C. The MR imaging was
performed using a dedicated small animal scanner operating at
9.4 T (Varian, Yarnton, UK), equipped with a Millipede volume
coil with an inner diameter of 30 mm. After positioning the animal
in the isocenter, short axis cine data were acquired (slice thickness,
1 mm; field of view, 25.0  25.0 mm2; matrix size, 128  128; flip
angle, 15; time to echo, 1.44 ms; and repetition time, 2.88 ms,
resulting in 51 frames in the cine train of 150 ms). The data acqui-
sition was triggered to start at the first R-wave in each expiration
period. The left ventricle was covered in 9–11 slices, which were ac-
quired sequentially.
The data were first saved in the nifty format and merged to 4D
stacks using FSL,55 which were opened using Amide,56 only to
save as dicom using the dcmtk library. The dicom data were im-
ported in Segment version 2.0 R5642 (http://segment.heiberg.se), a
freely available analysis software.57 For volumetric analysis, left
ventricular epicardial and endocardial contours were drawn manu-
ally in end diastole and end systole to calculate left ventricular
volumes and ejection fraction. For regional functional analysis, the
left ventricle in the short axis plane was divided into 16 segments
according to American Heart Association guidelines.58 Because
infarction was located in mid to apical LAD territory, the regional
wall thickness and function in the infarction area were analyzed
in segments 7, 8, 13, and 14. One investigator analyzed all the
images.
Statistical Analyses
Data are presented as mean ± SD. The negative binomial model was
used for RNaseq analyses. Statistical significance was determined by
Student’s t test (two-tail) between two groups, with normal distribu-
tions and similar variances, or with the Mann Whitney U test when
normal distribution was not detected. p < 0.05 was considered statis-
tically significant. All the experiments have been performed for at
least three biological replicates; no statistical method was used to pre-
determine sample size.
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